Aridis Pharmaceuticals is a private biotechnology company focusing on improved alternatives to traditional antibiotics for the treatment of pneumonia and Cystic Fibrosis in addition to a few other conditions. The company was founded in 2005 and is located in the San Francisco Bay Area. Aridis is run by successful industry veterans in the pharmaceutical field with experience in companies like Genentech and Medimmune. The company recently presented at the OneMedForum 2013 in New York City.
Aridis has a large product portfolio with its leading drug candidate being a first-in-class Anti-Sa mAb to treat pneumonia, which is currently in Phase II of it’s clinical trials. It is two years in advance of similar drugs being developed by Pfizer and Astra Zeneca and is also only 18 months away from receiving data from their Phase II trial. Furthermore, Aridis Pharmaceuticals has received Orphan Drug Status in Europe, and is applying to receive the same status in the United States as well.
In addition to the promising Anti-Sa mAb drug candidate, Aridis Pharmaceuticals has two drugs in the IND stage and a deep product pipeline as well. In the IND stage Aridis has Aerucin mAb, a drug to treat multiple strains of Pneumonia as well as Panaecin, a broad-spectrum drug for Cystic Fibrosis. Furthermore, in its product pipeline it is developing drugs to treat MDR AB and RSV infections in addition to using Panaecin as a treatment for wounds.
With its experienced management and deep pipeline Aridis has the potential to grow and be extremely successful in the pharmaceutical industry. In the coming year, as the company receives its clinical trial data, Aridis could potentially grow, assuming its trial results are successful. In addition to the $20 million of non-diluted grants that Aridis has received from the NIH to cover early drug development and testing in animals it is currently seeking $15 million in capital to finance its phase II clinical trials.
For more information on Aridis Pharmaceuticals visit their profile in the OneMedPlace database at Aridis Pharmaceuticals or visit their website at www.aridispharma.com. Reported by Proactive Investors 4 hours ago.
Aridis has a large product portfolio with its leading drug candidate being a first-in-class Anti-Sa mAb to treat pneumonia, which is currently in Phase II of it’s clinical trials. It is two years in advance of similar drugs being developed by Pfizer and Astra Zeneca and is also only 18 months away from receiving data from their Phase II trial. Furthermore, Aridis Pharmaceuticals has received Orphan Drug Status in Europe, and is applying to receive the same status in the United States as well.
In addition to the promising Anti-Sa mAb drug candidate, Aridis Pharmaceuticals has two drugs in the IND stage and a deep product pipeline as well. In the IND stage Aridis has Aerucin mAb, a drug to treat multiple strains of Pneumonia as well as Panaecin, a broad-spectrum drug for Cystic Fibrosis. Furthermore, in its product pipeline it is developing drugs to treat MDR AB and RSV infections in addition to using Panaecin as a treatment for wounds.
With its experienced management and deep pipeline Aridis has the potential to grow and be extremely successful in the pharmaceutical industry. In the coming year, as the company receives its clinical trial data, Aridis could potentially grow, assuming its trial results are successful. In addition to the $20 million of non-diluted grants that Aridis has received from the NIH to cover early drug development and testing in animals it is currently seeking $15 million in capital to finance its phase II clinical trials.
For more information on Aridis Pharmaceuticals visit their profile in the OneMedPlace database at Aridis Pharmaceuticals or visit their website at www.aridispharma.com. Reported by Proactive Investors 4 hours ago.